UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 67

Sortiert nach

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome

ACR open rheumatology, 2022-08, Vol.4 (8), p.689-699

2022

Link zum Volltext

Verfügbarkeit prüfen

A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes

Immunologic research, 2015-12, Vol.63 (1-3), p.90-100

2015

Link zum Volltext

Verfügbarkeit prüfen

Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells

Clinical cancer research, 2021-10, Vol.27 (20), p.5647-5659

2021

Link zum Volltext

Verfügbarkeit prüfen

Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions

Annals of the rheumatic diseases, 2015-09, Vol.74 (9), p.1734-1738

2015

Link zum Volltext

Verfügbarkeit prüfen

Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy

Annals of the rheumatic diseases, 2014-05, Vol.73 (5), p.909-912

2014

Link zum Volltext

Verfügbarkeit prüfen

A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma

Clinical cancer research, 2004-09, Vol.10 (17), p.5692-5701

2004

Link zum Volltext

Verfügbarkeit prüfen

The impact of attaining a minimal disease state after high‐dose melphalan and autologous transplantation for multiple myeloma

British journal of haematology, 2001-03, Vol.112 (3), p.814-819

2001

Link zum Volltext

Verfügbarkeit prüfen

Response to Dr Bredemeier's letter

Annals of the rheumatic diseases, 2014-06, Vol.73 (6), p.e34-e34

2014

Link zum Volltext

Verfügbarkeit prüfen

Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis

Annals of the rheumatic diseases, 2013-03, Vol.72 (3), p.463-464

2013

Link zum Volltext

Verfügbarkeit prüfen

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Leukemia, 2022-07, Vol.36 (7), p.1720-1748

2022

Link zum Volltext

Verfügbarkeit prüfen

High-Producer Haplotypes of Tumor Necrosis Factor Alpha and Lymphotoxin Alpha Are Associated With an Increased Risk of Myeloma and Have an Improved Progression-Free Survival After Treatment

Journal of clinical oncology, 2000-08, Vol.18 (15), p.2843-2851

2000

Link zum Volltext

Verfügbarkeit prüfen

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

Blood, 2022-11, Vol.140 (Supplement 1), p.7032-7033

2022

Link zum Volltext

Verfügbarkeit prüfen

B cell biomarkers of rituximab responses in systemic lupus erythematosus

Arthritis and rheumatism, 2011-10, Vol.63 (10), p.3038-3047

2011

Link zum Volltext

Verfügbarkeit prüfen

A molecular study of the t(4;14) in multiple myeloma

British journal of haematology, 2002-08, Vol.118 (2), p.514-520

2002

Link zum Volltext

Verfügbarkeit prüfen

Minimal residual disease monitoring in multiple myeloma

Best practice & research. Clinical haematology, 2002-03, Vol.15 (1), p.197-222

2002

Link zum Volltext

Verfügbarkeit prüfen

Reduced‐dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion

Arthritis and rheumatism, 2011-03, Vol.63 (3), p.603-608

2011

Link zum Volltext

Verfügbarkeit prüfen

Controversies surrounding the clonogenic origin of multiple myeloma

British journal of haematology, 2000-07, Vol.110 (1), p.240-241

2000

Link zum Volltext

Verfügbarkeit prüfen

FICTION‐TSA analysis of the B‐cell compartment in myeloma shows no significant expansion of myeloma precursor cells

British journal of haematology, 1999-07, Vol.106 (1), p.40-46

1999

Link zum Volltext

Verfügbarkeit prüfen

Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage

British journal of haematology, 1997-04, Vol.97 (1), p.46-55

1997

Link zum Volltext

Verfügbarkeit prüfen

B‐lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B‐cell progenitors and plasma cell precursors

British journal of haematology, 1998-01, Vol.100 (1), p.176-183

1998

Link zum Volltext

Verfügbarkeit prüfen

Expression Levels of a Single Gene, Lymphoid Enhancer Binding Factor 1, Discriminates CLL B-Cells from Other B-Cell Malignancies

Blood, 2007-11, Vol.110 (11), p.1113-1113

2007

Link zum Volltext

Verfügbarkeit prüfen

Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study

Blood, 2007-11, Vol.110 (11), p.3593-3593

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(67)

Sprache

Englisch
(67)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(39)
Life Sciences & Biomedicine
(36)
Science & Technology
(36)
Middle Aged
(23)
Aged
(22)
Female
(22)
Male
(22)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Hematology
(20)
Adult
(17)
Flow Cytometry
(15)
Aged, 80 And Over
(11)
Hematologic And Hematopoietic Diseases
(9)
Immunophenotyping
(9)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(9)
Immunodeficiencies. Immunoglobulinopathies
(8)
Immunoglobulinopathies
(8)
Immunopathology
(8)
Multiple Myeloma
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome

A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes

Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells

Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions

Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy

A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma

The impact of attaining a minimal disease state after high‐dose melphalan and autologous transplantation for multiple myeloma

Inherited genetic susceptibility to monoclonal gammopathy of unknown significance

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis

Response to Dr Bredemeier's letter

Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

High-Producer Haplotypes of Tumor Necrosis Factor Alpha and Lymphotoxin Alpha Are Associated With an Increased Risk of Myeloma and Have an Improved Progression-Free Survival After Treatment

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

B cell biomarkers of rituximab responses in systemic lupus erythematosus

A molecular study of the t(4;14) in multiple myeloma

Minimal residual disease monitoring in multiple myeloma

Reduced‐dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion

Controversies surrounding the clonogenic origin of multiple myeloma

FICTION‐TSA analysis of the B‐cell compartment in myeloma shows no significant expansion of myeloma precursor cells

Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage

B‐lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B‐cell progenitors and plasma cell precursors

Expression Levels of a Single Gene, Lymphoid Enhancer Binding Factor 1, Discriminates CLL B-Cells from Other B-Cell Malignancies

Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study

Suchergebnisse filtern